Thalidasine
Thalidasine (compound 3) is a bisbenzyltetrahydroisoquinoline alkaloid. Thalidasine is a anticancer agent against human colon adenocarcinoma cells. Thalidasine exhibits antileishmanial activity and can be used for Leishmania infection research research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 16623-56-6
- Formule: C39H44N2O7
- Masse moléculaire:652.78
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | IC50 |
5.5 μM
Compound: 3
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 25629555] |
Chemical Information
-
CAS No. 16623-56-6
-
Masse moléculaire 652.78
-
Formule C39H44N2O7
-
SMILES
COC1=CC(CCN2C)=C(C(OC3=C(OC)C(OC)=CC4=C3CCN(C)[C@H]4CC5=CC=C(O6)C=C5)=C1OC)[C@@H]2CC7=CC=C(OC)C6=C7
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Thalidasine Related Classifications
HY-N15413 Related Classifications
Powered by Bioz